Effect of duodenal levodopa infusion on blood pressure and sweating

Acta Neurologica Scandinavica

Volumn 126, Issue 4, 2012, Pages

  Pursiainen, V ^a,b   Lyytinen, J ^a   Pekkonen, E ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Autonomic nervous system; Levodopa; Non motor symptoms; Parkinson's disease

Indexed keywords

LEVODOPA;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY BURDEN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DUODENUM; DYSKINESIA; HEART RATE; HUMAN; INTERPERSONAL COMMUNICATION; MALE; MOTOR PERFORMANCE; NON MOTOR SYMPTOM SCALE; ORTHOSTATIC BLOOD PRESSURE; PARKINSON DISEASE; PARKINSONS DISEASE RATING SCALE; PDQ 39; PHYSICAL MOBILITY; QUALITY OF LIFE; RATING SCALE; SKIN TEMPERATURE; SUPINE POSITION; SWEATING; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; BLOOD PRESSURE; DRUG ADMINISTRATION ROUTES; DUODENUM; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SWEATING; TREATMENT OUTCOME;

EID: 84865710974     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2012.01648.x     Document Type: Article

References (19)

1. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9(Suppl. 2):S73-81.
2. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
3. Senard JM, Raï S, Lapeyre-Mestre M et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-9.
4. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
5. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
6. Santos-García D, Sanjurjo LF, Macías M, Llaneza M, Carpintero P, de la Fuente-Fernández R. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand 2011. DOI: 10.1111/j.1600-0404.2011.01523.x [Epub ahead of print].
7. Fahn S, Elton RL & The members of the UPDRS Development Committee (1987) UPDRS: Unified Parkinson's Disease Rating Scale. In: Fahn S, Mardsen CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healt Care Information, 1987;153-64.
8. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatr 1988;39:1172-7.
9. Nuutinen J, Alanen E, Autio P, Lahtinen M-R, Harvima I, Lahtinen T. A closed unventilated chamber for the measurement of transepidermal water loss. Skin Res Technol 2003;9:85-9.
10. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22:1901-11.
11. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7.
12. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
13. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-56.
14. Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:742-5.
15. Haapaniemi TH, Kallio MA, Korpelainen JT et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol 2000;247:868-74.
16. Bouhaddi M, Vuillier F, Fortrat JO et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton Neurosci 2004;116:30-8.
17. Worth D, Harvey J, Brown J, Lee M. The effects of intravenous L-dopa on plasma renin activity, renal function, and blood pressure in man. Eur J Clin Pharmacol 1988;35:137-41.
18. Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllylä VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord 2007;22:828-32.
19. Sage JI, Margery HM. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Ann Neurol 1995;37:120-2.